Rationale and design of the Department of Veterans Affairs high-density lipoprotein cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol
References (56)
- et al.
Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease
Am J Cardiol
(1990) - et al.
Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with “desirable” total cholesterol levels
Am J Cardiol
(1991) - et al.
Prevalence of risk factors in men with premature coronary artery disease
Am J Cardiol
(1991) - et al.
National Cholesterol Education Program's recommendations, and implications of “missing” high-density lipoprotein cholesterol in cardiac rehabilitation programs
Am J Cardiol
(1991) - et al.
Protein-lipids relationships in human plasma. II. In atherosclerosis and related conditions
Am J Med
(1951) - et al.
High density lipoprotein as a protective factor against coronary heart disease
Am J Med
(1977) - et al.
The Trømso Heart Study: high density lipoprotein and coronary heart-disease: a prospective case control study
Lancet
(1977) The plasma lecithin:cholesterol acyltransferase reaction
J Lipid Res
(1968)Drug treatment of dyslipoproteinemia
Endocrinol Metab Clin North Am
(1990)- et al.
A new epidemiologic classification system for interim myocardial infarction from serial electrocardiographic changes
Am J Cardiol
(1989)
Sample size determination in clinical trials with time-dependent rates of losses and noncompliance
Controlled Clin Trials
The place of HDL in cholesterol management: A perspective from the National Cholesterol Education Program
Arch Intern Med
Chronic ischemic heart disease
Cholesterol, primary and secondary prevention, and all-cause mortality
Ann Intern Med
Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
N Engl J Med
Reduced high density lipoproteins as a risk factor after acute myocardial infarction
Acta Med Scand
Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults
Arch Intern Med
High-density lipoprotein — the clinical implications of recent studies
N Engl J Med
Prospective Cardiovascular Meunster Trial
Cholesterol in the prediction of atherosclerotic disease: new perspectives based on the Framingham Study
Ann Intern Med
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction
N Engl J Med
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
JAMA
High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: The Lipid Research Clinics Coronary Primary Prevention Trial
Circulation
Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
JAMA
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
N Engl J Med
Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
N Engl J Med
Cited by (90)
The complexity of HDL
2010, Biochimica et Biophysica Acta - Molecular and Cell Biology of LipidsCitation Excerpt :Following the initial demonstration of the correlation between low levels of plasma alpha lipoproteins and increased risk for CAD [1], large population studies including the Framingham Heart Study [2], the Lipid Research Clinics Prevalence Study [3], the Trømso Heart Study [4], the Prospective Cardiovascular Münster Trial [5], the Physician's Health Study [6], and others [7] confirmed this relationship, with several of these studies indicating a low level of HDL-C to be the single strongest predictor of CAD events [8]. This relationship is independent of other major coronary risk factors, as well as plasma triglyceride levels [9], and is present in both men and women, the elderly, and those with and without CAD at baseline [8]. Confounding this general population trend, however, are genetic HDL deficiency states that are frequently but not always associated with increased risk for atherosclerosis.
Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial
2009, American Heart JournalCitation Excerpt :The VA-HIT was a multicenter, double-blinded, randomized controlled trial that tested whether gemfibrozil was effective in secondary prevention of CHD in men with low levels of high-density lipoprotein. Trial design and results have previously been published elsewhere.12,14 Briefly, men <74 years old with a history of CHD, high-density lipoprotein cholesterol ≤40 mg/dL (≤3.6 mmol/L), low-density lipoprotein cholesterol ≤140 mg/dL, and triglyceride level ≤300 mg/dL were randomized to gemfibrozil 1,200 mg/d or matching placebo.
Lipid Management in the Geriatric Patient
2009, Endocrinology and Metabolism Clinics of North AmericaRosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells
2008, Metabolism: Clinical and ExperimentalStatin, the black box
2008, Archives of Cardiovascular Diseases
- ∗
See Appendix.